Regulation of mTOR signaling by semaphorin 3F-neuropilin 2 interactions in vitro and in vivo

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nakayama, Hironao ^a,b   Bruneau, Sarah ^a   Kochupurakkal, Nora ^a   Coma, Silvia ^a   Briscoe, David M ^a   Klagsbrun, Michael ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b EHIME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE PROTEIN; MULTIPROTEIN COMPLEX; NERVE PROTEIN; NEUROPILIN 2; PROTEIN BINDING; PROTEIN KINASE B; S6 KINASE; SEMA3F PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; VASCULOTROPIN A;

ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; HUMAN; HYPOXIA; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ACTINS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; HYPOXIA; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; NEUROPILIN-2; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937019661     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11789     Document Type: Article

References (60)

1. Klagsbrun, M. & Eichmann, A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 16, 535-548 (2005).
2. Neufeld, G. & Kessler, O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8, 632-645 (2008).
3. Giger, R. J., Urquhart, E. R., Gillespie, S. K., Levengood, D. V., Ginty, D. D. & Kolodkin, A. L. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 21, 1079-1092 (1998).
4. Takahashi, T. & Strittmatter, S. M. Plexina1 autoinhibition by the plexin sema domain. Neuron 29, 429-439 (2001).
5. Bielenberg, D. R. et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114, 1260-1271 (2004).
6. Shimizu, A. et al. ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. J Biol Chem 283, 27230-27238 (2008).
7. Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252-256 (2013).
8. Hansen, W. et al. Neuropilin 1 deficiency on CD4+ Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 209, 2001-2016 (2012).
9. Kumanogoh, A. & Kikutani, H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol 13, 802-814 (2013).
10. Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 209, 1723-1742, s1721 (2012).
11. Bielenberg, D. R. et al. Increased smooth muscle contractility in mice deficient for neuropilin 2. Am J Pathol 181, 548-559 (2012).
12. Procaccia, V., Nakayama, H., Shimizu, A. & Klagsbrun, M. Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility. Biochem Biophys Res Commun 448, 134-138 (2014).
13. Potiron V. A. et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 67, 8708-8715 (2007).
14. Nukazuka, A., Tamaki, S., Matsumoto, K., Oda, Y., Fujisawa, H. & Takagi, S. A shift of the TOR adaptor from Rictor towards Raptor by semaphorin in C. elegans. Nat Commun 2, 484 (2011).
15. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
16. Sancak, Y. et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903-915 (2007).
17. Pearce, L. R. et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405, 513-522 (2007).
18. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302 (2004).
19. Yang, Q., Inoki, K., Ikenoue, T. & Guan, K. L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20, 2820-2832 (2006).
20. Sarbassov, D. D., Ali, S. M. & Sabatini, D. M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17, 596-603 (2005).
21. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
22. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
23. Garcia-Martinez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375-385 (2008).
24. Dormond, O., Dufour, M., Seto, T., Bruneau, S. & Briscoe, D. M. Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol 73, 1261-1268 (2012).
25. Gamper, C. J. & Powell, J. D. All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol 3, 312 (2012).
26. Powell, J. D. & Delgoffe, G. M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33, 301-311 (2010).
27. Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 159-170 (2006).
28. Mendes-da-Cruz, D. A. et al. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. PLoS One 9, e103405 (2014).
29. Flaxenburg, J. A., Melter, M., Lapchak, P. H., Briscoe, D. M. & Pal, S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol 172, 7503-7509 (2004).
30. Kang, S. A. et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341, 1236566 (2013).
31. Pollizzi, K. N. & Powell, J. D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 14, 435-446 (2014).
32. Bruneau, S., Nakayama, H., Woda, C. B., Flynn, E. A. & Briscoe, D. M. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood 122, 1833-1842 (2013).
33. Dazert, E. & Hall, M. N. mTOR signaling in disease. Curr Opin Cell Biol 23, 744-755 (2011).
34. Phung, T. L. et al. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 67, 5070-5075 (2007).
35. Shimobayashi, M. & Hall, M. N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15, 155-162 (2014).
36. Dormond, O. et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 181, 8088-8095 (2008).
37. Dormond, O., Madsen, J. C. & Briscoe, D. M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282, 23679-23686 (2007).
38. Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M. & Manning, B. D. S6K1 regulates GSK3 under conditions of mTORdependent feedback inhibition of Akt. Mol Cell 24, 185-197 (2006).
39. Burridge, K. & Wennerberg, K. Rho and Rac take center stage. Cell 116, 167-179 (2004).
40. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10, 417-427 (2011).
41. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
42. Karar, J. & Maity, A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4, 51 (2011).
43. Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117-1133 (2011).
44. Cao, Y. et al. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Res 73, 4579-4590 (2013).
45. Sabag, A. D., Bode, J., Fink, D., Kigel, B., Kugler, W. & Neufeld, G. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS One 7, e42912 (2012).
46. Gan, X., Wang, J., Su, B. & Wu, D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 286, 10998-11002 (2011).
47. Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 144, 757-768 (2011).
48. Levitt, R. J., Georgescu, M. M. & Pollak, M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336, 1056-1061 (2005).
49. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410-3415 (1998).
50. Wen, S. et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 98, 4622-4627 (2001).
51. Cai, H. & Reed, R. R. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 19, 6519-6527 (1999).
52. Katoh, M. Functional proteomics, human genetics and cancer biology of GIPC family members. Exp Mol Med 45, e26 (2013).
53. Wang, L., Mukhopadhyay, D. & Xu, X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. Faseb j 20, 1513-1515 (2006).
54. Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886 (2009).
55. Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128 (2004).
56. Kessler, O. et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64, 1008-1015 (2004).
57. Kigel, B., Varshavsky, A., Kessler, O. & Neufeld, G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 3, e3287 (2008).
58. Sekulic, A. et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60, 3504-3513 (2000).
59. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S. & Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17, 5629-5639 (1997).
60. Bielenberg, D. R., Shimizu, A. & Klagsbrun, M. Semaphorin-induced cytoskeletal collapse and repulsion of endothelial cells. Methods Enzymol 443, 299-314 (2008).